RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Citius Pharmaceuticals Stock

Citius Pharmaceuticals Net Income 2024

Citius Pharmaceuticals Net Income

-1.7 M USD

Ticker

CTXR

ISIN

US17322U2078

WKN

A2DXS0

In 2024, Citius Pharmaceuticals's profit amounted to -1.7 M USD, a -94.97% increase from the -33.69 M USD profit recorded in the previous year.

The Citius Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2030e-
2029e-
2028e-
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-
2011-

Citius Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Citius Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Citius Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Citius Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Citius Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Citius Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Citius Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Citius Pharmaceuticals’s growth potential.

Citius Pharmaceuticals Revenue, EBIT and net profit per share

DateCitius Pharmaceuticals RevenueCitius Pharmaceuticals EBITCitius Pharmaceuticals Net Income
2030e0 undefined0 undefined0 undefined
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined

Citius Pharmaceuticals stock margins

The Citius Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Citius Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Citius Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Citius Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Citius Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Citius Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Citius Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Citius Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Citius Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Citius Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Citius Pharmaceuticals Margin History

Citius Pharmaceuticals Gross marginCitius Pharmaceuticals Profit marginCitius Pharmaceuticals EBIT marginCitius Pharmaceuticals Profit margin
2030e0 %0 %0 %
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %

Citius Pharmaceuticals Aktienanalyse

What does Citius Pharmaceuticals do?

Citius Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for unmet medical needs. The company was founded in 2006 and is headquartered in Cranford, New Jersey. Business Model Citius Pharmaceuticals' business model is based on the development of drugs and therapies for rare and unmet medical needs. The company utilizes its industry experience and knowledge to identify unmet medical needs and develop novel therapeutic approaches. Citius Pharmaceuticals collaborates closely with leading academic and scientific institutions to expedite and enhance the effectiveness of its development projects. History Citius Pharmaceuticals was founded by Myron Holubiak, who has over 30 years of experience in the pharmaceutical and biotech industry. Holubiak previously led drug development efforts for companies such as 3M Pharmaceuticals and Elan Pharmaceuticals. In 2007, Citius Pharmaceuticals went public to raise capital for its development projects. Products and Divisions Citius Pharmaceuticals operates in two main divisions: the first focuses on the development of drugs for rare and unmet medical needs, while the second concentrates on the development of therapies for common conditions such as hemorrhoids and cold sores. One of Citius Pharmaceuticals' products is Mino-Lok®, a medication for the treatment of severe intravenous catheter infections. This product is designed to reduce the need for antibiotics commonly used in such infections. Mino-Lok® is currently in Phase III clinical development. Another product by Citius Pharmaceuticals is Halo-Lido, a new therapy for hemorrhoids. It contains lidocaine and hydrocortisone acetate, and is developed to reduce pain and inflammation associated with hemorrhoids. Halo-Lido has already been approved by the US Food and Drug Administration (FDA) and is currently available on the market. Additionally, Citius Pharmaceuticals has a portfolio of patented and trademarked products that provide a platform for future growth. The company is also working on the development of new therapies for cold sores and other viral infections. Conclusion Citius Pharmaceuticals Inc. is an innovative biopharmaceutical company that identifies the needs of unmet medical areas and develops innovative solutions for treating these conditions. With an experienced management team and a strong portfolio of patented products, Citius Pharmaceuticals is well positioned to continue growing and increasing value for its stakeholders. Citius Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Citius Pharmaceuticals's Profit Margins

The profit margins of Citius Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Citius Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Citius Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Citius Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Citius Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Citius Pharmaceuticals stock

How much profit has Citius Pharmaceuticals made this year?

Citius Pharmaceuticals has made -1.7 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -94.97% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Citius Pharmaceuticals publish its earnings?

Citius Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Citius Pharmaceuticals?

The profits of Citius Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Citius Pharmaceuticals?

You can learn more about the earnings of Citius Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Citius Pharmaceuticals pay?

Over the past 12 months, Citius Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Citius Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Citius Pharmaceuticals?

The current dividend yield of Citius Pharmaceuticals is .

When does Citius Pharmaceuticals pay dividends?

Citius Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Citius Pharmaceuticals?

Citius Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Citius Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Citius Pharmaceuticals located?

Citius Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Citius Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Citius Pharmaceuticals from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Citius Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Citius Pharmaceuticals in the year 2023?

In the year 2023, Citius Pharmaceuticals distributed 0 USD as dividends.

In which currency does Citius Pharmaceuticals pay out the dividend?

The dividends of Citius Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Citius Pharmaceuticals

Our stock analysis for Citius Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Citius Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.